Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Open Access
- 31 March 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (7) , 1653-1662
Abstract
Purpose: By integrating expression profiles of mRNAs and long noncoding RNAs (lncRNA), we tried to develop and validate novel multigene signatures to facilitate individualized treatment of triple-negative breast cancer (TNBC) patients. Experimental Design: We analyzed 165 TNBC samples and 33 paired normal breast tissues using transcriptome microarrays. Tumor-specific mRNAs and lncRNAs were identified and correlated with patients' recurrence-free survival (RFS). Using Cox regression model, we built two multigene signatures incorporating mRNAs and lncRNAs. The prognostic and predictive accuracy of the signatures were tested in a training set of 165 TNBC patients and validated in other 101 TNBC patients. Results: We successfully developed an mRNA and an integrated mRNA–lncRNA signature based on eight mRNAs and two lncRNAs. In the training set, patients in the high-risk group were more likely to suffer from recurrent disease than patients in the low-risk group in both signatures [HR, 10.00; 95% confidence interval (CI), 2.53–39.47, P = 0.001; HR = 4.46, 95% CI, 1.34–14.91, P = 0.015 for integrated signature and mRNA signature, respectively). Results were validated in the validation set (P = 0.019 and 0.030, respectively). In addition, time-dependent receiver operating curve showed that the integrated mRNA–lncRNA signature had a better prognostic value than both the eight-mRNA-only signature and the clinicopathologic risk factors in both sets. We also found through interaction analysis that patients classified into the low-risk group by the integrated mRNA–lncRNA signature had a more favorable response to adjuvant taxane chemotherapy. Conclusions: The multigene signature we developed can accurately predict clinical outcome and benefit of taxane chemotherapy in TNBC patients. Clin Cancer Res; 22(7); 1653–62. ©2016 AACR.Keywords
All Related Versions
Funding Information
- Fudan University (YJ201401)
- National Natural Science Foundation of China (81572583, 81502278, 81372848, 81370075)
- Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals (SHDC12010116)
- Cooperation Project of Conquering Major Diseases in Shanghai Municipality Health System (2013ZYJB0302)
- Innovation team of Ministry of Education (IRT1223)
- Shanghai Key Laboratory of Breast Cancer (12DZ2260100)
This publication has 35 references indexed in Scilit:
- CDK‐mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC‐driven transcription and tumourigenesis and predicts poor survival in breast cancerEMBO Molecular Medicine, 2013
- Molecular Mechanisms of Long Noncoding RNAsMolecular Cell, 2011
- Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancerBreast Cancer Research and Treatment, 2011
- Cyclin-dependent Kinase-mediated Phosphorylation of RBP1 and pRb Promotes Their Dissociation to Mediate Release of the SAP30·mSin3·HDAC Transcriptional Repressor ComplexJournal of Biological Chemistry, 2011
- Role of H3K27 methylation in the regulation of lncRNA expressionCell Research, 2010
- Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisNature, 2010
- Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II diseaseBritish Journal of Cancer, 2008
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002